Endologix (NASDAQ:ELGX) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday.
A number of other equities research analysts also recently commented on ELGX. Oppenheimer set a $5.00 target price on Endologix and gave the company a “hold” rating in a report on Thursday, February 22nd. Stifel Nicolaus reduced their target price on Endologix from $6.00 to $5.50 and set a “hold” rating for the company in a report on Wednesday, November 8th. BidaskClub downgraded Endologix from a “buy” rating to a “hold” rating in a report on Friday, December 15th. Canaccord Genuity reissued a “hold” rating and issued a $5.00 target price on shares of Endologix in a report on Wednesday, November 8th. Finally, Zacks Investment Research downgraded Endologix from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company’s stock. Endologix presently has an average rating of “Hold” and a consensus price target of $5.41.
Shares of Endologix (ELGX) traded up $0.07 during midday trading on Thursday, hitting $4.09. The company had a trading volume of 567,626 shares, compared to its average volume of 767,076. The company has a current ratio of 2.90, a quick ratio of 2.11 and a debt-to-equity ratio of 2.61. Endologix has a 52-week low of $3.75 and a 52-week high of $7.66. The firm has a market capitalization of $342.16, a P/E ratio of -5.11 and a beta of 0.42.
Large investors have recently added to or reduced their stakes in the company. Alliancebernstein L.P. raised its stake in shares of Endologix by 11.5% during the 2nd quarter. Alliancebernstein L.P. now owns 108,757 shares of the medical instruments supplier’s stock worth $529,000 after buying an additional 11,200 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Endologix by 211.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 109,380 shares of the medical instruments supplier’s stock worth $488,000 after buying an additional 74,227 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Endologix by 40.8% during the 2nd quarter. Teachers Advisors LLC now owns 198,912 shares of the medical instruments supplier’s stock worth $967,000 after buying an additional 57,675 shares during the last quarter. State Street Corp raised its stake in shares of Endologix by 11.5% during the 2nd quarter. State Street Corp now owns 1,951,432 shares of the medical instruments supplier’s stock worth $9,483,000 after buying an additional 201,700 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Endologix by 5.0% during the 2nd quarter. Northern Trust Corp now owns 1,104,943 shares of the medical instruments supplier’s stock worth $5,369,000 after buying an additional 52,755 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3231820/endologix-elgx-stock-rating-lowered-by-valuengine.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.